Loyola University Medical Center Maywood, IL, United States
Adnan Malik, MD1, Mahum Nadeem, MD2, Maryam Haider, MD3, Sadia Javaid, MBBS4 1Loyola University Medical Center, Maywood, IL; 2University of Oklahoma Health Sciences Center, Oklahoma City, OK; 3Wayne State University, Detroit Medical Center, Detroit, MI; 4Nishtar Hospital, Multan, Punjab, Pakistan
Introduction: Crohn`s disease (CD) is a chronic relapsing idiopathic bowel disease. Vedolizumab (VDZ) is a monoclonal antibody that targets the a4b7 integrin. It inhibits the migration of the lymphocytes into the gut. Many previous studies have demonstrated the efficacy of VDZ in increasing the rates of remission and response in patients with CD.
In this meta-analysis, we aim to evaluate the efficacy of vedolizumab in patients with Crohn's disease.
Methods: We systemically searched Cochrane CENTRAL, PubMed, Web of Science, and SCOPUS databases for relevant studies assessing the efficacy and/or safety of vedolizumab in CD. We performed the analysis using pooled proportion and relative 95% confidence interval (CI). All heterogeneous data were analyzed under the random-effects model. Our primary efficacy outcomes included the rates of clinical response, steroid-free remission, and clinical remission. Secondary safety endpoints included the incidence of Any Adverse Events, Infections, and arthralgia. We also performed a subgroup analysis according to the duration of treatment.
Results: We included 14 studies. The average duration of treatment was 32 weeks. The results of our analysis revealed that Clinical Response was achieved in 58.2% of patients (95% CI [46.9%, 69.4%]), Steroid-free remission was achieved in 32.7% (95% CI [26%, 39.4%]), and Clinical Remission in 40.8% (95% CI [33.4%, 48.2%]). Regarding safety endpoints, the incidence of any Adverse Events was 65.3%, Infections was 17.9%, and Arthralgia was 6.5%.
Discussion: The results after an average of 32 weeks of therapy confirm that vedolizumab is effective in inducing long-term clinical response, clinical remission, and steroid-free remission, with infection rates comparable to those with anti-TNF treatment or without biologic therapy.
Adnan Malik indicated no relevant financial relationships.
Mahum Nadeem indicated no relevant financial relationships.
Maryam Haider indicated no relevant financial relationships.
Sadia Javaid indicated no relevant financial relationships.
Adnan Malik, MD1, Mahum Nadeem, MD2, Maryam Haider, MD3, Sadia Javaid, MBBS4. P2621 - Efficacy of Vedolizumab in Increasing the Rates of Remission and Response in Patients With CD: A Systematic Review and Meta-Analysis, ACG 2021 Annual Scientific Meeting Abstracts. Las Vegas, Nevada: American College of Gastroenterology.